Synthesis, Biological Activity, and Quantitative Structure-Activity Relationship Study of Azanaphthalimide and Arylnaphthalimide Derivatives

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2236-2242

  Braña, Miguel F ^a   Gradillas, Ana ^a   Gómez, Angel ^a   Acero, Nuria ^a   Llinares, Francisco ^a   Muñoz Mingarro, Dolores ^a   Abradelo, Cristina ^a   Rey Stolle, Fernanda ^a   Yuste, Mercedes ^a   Campos, Joaquín ^b   Gallo, Miguel A ^b   Espinosa, Antonio ^b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZANAPHTHALIMIDE; NAPHTHALENE; NAPHTHALIMIDE; QUINOLINE DERIVATIVE; TRICYCLIC AROMATIC COMPOUND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CHROMATOPHORE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVITY; DRUG DNA INTERACTION; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDES; NAPHTHALENES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 11144354895     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0310784     Document Type: Article

References (36)

1. Braña, F. M.; Cacho, M.; Gradillas, A.; Pascual-Teresa, B.; Ramos A. Intercalators as Anticancer Drugs. Curr. Pharm. Des. 2001, 7, 1745-1780.
2. Braña, M. F.; Ramos, A. Naphathalimides as Anticancer Agents: Synthesis and Biological Activity. Curr. Med. Chem.: Anti-Cancer Agents 2001, 1, 237-255.
3. Malviya, V. K.; Liu, P. Y.; Alberts, D. S.; Surwit, E. A.; Craig, J. B.; Hanningan, E. V. Evaluation of Amonafide in Cervical Cancer, Phase II. A SWOG Study. Am. J. Clin. Oncol. 1992, 15, 41-44.
4. Hsiang, Y.-H.; Jiang, J. B.; Liu, L. F. Topoisomerase II-Mediated DNA Cleavage by Amonafide and Its Structural Analogs. Mol. Pharmacol. 1989, 36, 371-376.
5. Bousquet, P. F.; Braña, M. F.; Conlon, D.; Fitzgerald, K. M.; Perron, D.; Cocchiaro, C., Miller, R.; Moran, M.; George, J.; Qian, X.-D.; Keilhauer, G.; Romerdahl, C. Preclinical Evaluation of LU79553: A Novel Bis-naphathalimide with Potent Antitumor Activity. Cancer Res. 1995, 55, 1176-1180.
6. Bailly, C.; Carrasco, C.; Joubert, A.; Bal, C.; Wattez, N.; Hildebrand, M.-P.; Lansiaux, A.; Colson, P.; Houssier, C.; Cacho, M.; Ramos, A.; Braña, M. F. Chromophore-Modified Bis-naphthalimides: DNA Recognition, Topoisomerase Inhibition and Cytotoxic Properties of Two Mono- and Bis-furonaphthalimides. Biochemistry 2003, 42, 4136-4150.
7. Braña, F. M.; Cacho, M.; Garcia, M. A.; Pascual-Teresa, B.; Ramos, A.; Acero, N.; Llinares, F.; Muñoz-Mingarro, D.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M. Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties of a New Series of Imidazonaphthalimides. J. Med. Chem. 2002, 50, 5813-5816.
8. Braña, F. M.; Cacho, M.; Ramos, A.; Dominguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Carrasco, C.; Bailly, C. Synthesis, Biological Evaluation, and DNA Binding Properties of Novel Mono and Bisnaphthalimides. Org. Biomol. Chem. 2003, 1, 648-654.
9. Cheng, C. C. Structural Aspects of Antineoplastic Agents-A New Approach. In Progress of Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Science Publishers, B. V. (Biomedical Division): Amsterdam, 1988; Vol. 25, pp 35-83.
10. Atwell, G. A.; Baguley, B. C.; Denny, W. A. Potential Antitumor Agents. 57. 2-Phenylquinoline-8-carboxamides as "Minimal" DNA-Intercalating Antitumor Agents with in Vivo Solid Tumor Activity. J. Med. Chem. 1989, 32, 396-401.
11. Joule, J. A.; Mills, K.; Smith, G. F. Heterocyclic Chemistry, 3rd ed. Chapman & Hall: London, 1995; pp 135-136.
12. Waldmann, H. Isatincarboxilic Acid. J. Prakt. Chem. 1937, 147, 338-343.
13. Raveglia, F. L.; Giardina, M. A. G.; Grugni, M.; Rigoli, R.; Farina, C. A Novel Synthesis of 3-Halo-2-phenylquinoline-4-carboxilic Acids. J. Heterocycl. Chem. 1997, 34, 557-559.
14. Giardina, M. A. G.; Sarau, M. H.; Farina, C.; Medhurst, D. A.; Grugni, M.; Raveglia, L. F.; Schmidt, D. B.; Rigolio, R.; Luttmann, M.; Vecchietti, V.; Hay, D. W. P. Discovery of a Novel Class of Selective Non-peptide Antagonist for the Human Neurokinin-3-receptor. 1. Identification to the 4-Quinoline-carboxamide Framework. J. Med. Chem. 1997, 40, 1794-1807.
15. Jacobs, T. L.; Winstein, S.; Linden, G. B.; Robson, J. H.; Levi, E. F.; Seymour, D. 2-Hydroxycinchoninic Acid. Org. Synth. 1955, 456-458 (collective volume III).
16. Kaslow, C. E.; Lauer, W. M. 2-Chlorolepidine. Org. Synth. 1955, 194-195 (collective volume III).
17. Neumann, F. W.; Sommer, N. B.; Kaslow, C. E.; Shriner, R. L. Lepidine. Org. Synth. 1955, 519-522 (collective volume III).
18. Marvel, C. S.; Hiers, G. S. Isatin. Org. Synth. 1932, 327-330 (collective volume I).
19. Sun, J.-H.; Seitz, P. S. 3-Aromatic and 3-Heteroaromatic Substituted Bisnaphthalimides. Patent WO9625400, 1997.
20. Amegadzie, A. K.; Carey, M. E.; Domagala, J. M.; Micetich, R. G.; Singh, R.; Stier, M. A.; Vaisburg, A. Isoquinolones. Patent WO9819648, 1998.
21. PALLAS FRAME MODULE, a prediction tool of physicochemical parameters, is supplied by CompuDrug Chemistry Ltd., P.O. Box 23196, Rochester, NY 14692.
22. Wermuth, C. G. The Practice of Medicinal Chemistry; Academic Press: London, 1996; pp 367-389.
23. Hansch, C.; Garg, R.; Kurup, A. Searching for Allosteric Effects via QSARs. Bioorg. Med. Chem. 2001, 9, 283-289.
24. Garg, R.; Kurup, A.; Mekapati, S. B.; Hansch, C. Searching of Allosteric Effects via QSAR. Part. II. Bioorg. Med. Chem. 2003, 11, 621-628.
25. Garg, R.; Kurup, A.; Hansch, C. Possible Allosteric Effects in Anticancer Compounds. Bioorg. Med. Chem. 2001, 9, 3161-3164.
26. Acheson, R. M. An Introduction to the Chemistry of Heterocyclic Compounds; John Wiley & Sons: New York, 1976; pp 228-297.
27. Jones, G., Ed. Heterocyclic Compounds. Quinolines. Part 1; John Wiley & Sons: Chichester, U.K., 1977; Vol. 32, pp 558-560.
28. The theoretical antiproliferative activity of 16, calculated according to eq 1, is higher (7.04) than the experimental value (5.24).
29. Ren, J.; Jenkins, T. C.; Chaires, J. B. Energetics of DNA Intercalation Reactions. Biochemistry 2000, 39, 8439-8447.
30. Haq, I.; Jenkins, T. C.; Chowdhry, B. Z.; Ren, J.; Chaires, J. B. Parsing Free Energies of Drug-DNA Interactions. Methods Enzymol. 2000, 323, 373-405.
31. Cohen, G.; Eisenberg, H. Viscosity and Sedimentation Study of Sonicated DNA-Proflavine Complexes. Biopolymers 1969, 8, 45-55.
32. Waring, M. J.; González, A.; Jiménez, A.; Vázquez, D. Intercalative Binding to DNA of Antitumor drugs Derived from 3-Nitro-1,8-naphthalic Acid. Nucleics Acids Res. 1979, 7, 217-230.
33. Cory, M.; Mckee, D. D.; Kagan, J.; Henry, D. W.; Allen Miller, J. Design, Synthesis and DNA Binding Properties of Bifunctional Intercalators. Comparison of Polymethylene and Diphenyl Ether Chains Connecting Phenanthridine. J. Am. Chem. Soc. 1985, 107, 2528-2536.
34. Moinet-Hedin, V.; Tabka, T.; Poulain, L.; Godard, T.; Lechevrel, M.; Saturnino, C.; Lancelot, J. C.; Le Talaër, J. Y.; Gauduchon, P. Biological Properties of 5,11-dimethyl-6H-pyrido[3,2-b] carbazoles: A New Class of Potent Antitumor Drugs. Anti-Cancer Drug Des. 2000, 15, 109-118.
35. Eigner, J.; Doty, P. The Native, Denatured and Renatured States of Deoxyribonucleic Acid. J. Mol. Biol. 1965, 12, 549-580.
36. Muller, W.; Crothers, D. M. Interactions of Heteroaromatic Compounds with Nucleic Acids. 1. The Influence of Heteroatoms and Polarizability on the Base Specificity of Intercalating Ligands. Eur. J. Biochem. 1975, 54, 267-277.